Jeffrey S. Heier Sells 2,948 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the transaction, the insider now owns 269,059 shares in the company, valued at $2,424,221.59. The trade was a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Ocular Therapeutix Price Performance

Shares of OCUL stock opened at $10.06 on Friday. The stock’s 50-day moving average price is $9.96 and its 200-day moving average price is $8.22. Ocular Therapeutix, Inc. has a 12-month low of $2.16 and a 12-month high of $11.77. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Analyst Ratings Changes

A number of equities analysts recently commented on OCUL shares. HC Wainwright raised their target price on Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Scotiabank started coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective on the stock. Finally, Robert W. Baird cut their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC raised its stake in Ocular Therapeutix by 12.7% during the second quarter. Avoro Capital Advisors LLC now owns 8,060,000 shares of the biopharmaceutical company’s stock valued at $55,130,000 after purchasing an additional 911,064 shares in the last quarter. Vanguard Group Inc. grew its position in Ocular Therapeutix by 41.4% in the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock worth $65,840,000 after acquiring an additional 2,117,029 shares in the last quarter. Opaleye Management Inc. increased its stake in Ocular Therapeutix by 9.6% during the first quarter. Opaleye Management Inc. now owns 6,653,138 shares of the biopharmaceutical company’s stock worth $60,544,000 after acquiring an additional 583,138 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at approximately $24,584,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Ocular Therapeutix in the 2nd quarter worth approximately $18,514,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.